Press release
Ovarian Cancer Pipeline Analysis (2023 Updates) | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, Treatment Outlook, and Key Companies | Genentech, Genmab, Merck, ImmunoGen, Aravive,
"Ovarian Cancer Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Ovarian Cancer Therapeutics Market.
The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).
The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
Ovarian Cancer Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Ovarian Cancer Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Ovarian Cancer treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Ovarian Cancer market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Learn More about the Clinical and Commercial Development Activities in the Ovarian Cancer Therapeutics Domain:
https://www.delveinsight.com/report-store/ovarian-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
The Report Covers the Emerging Pipeline Products Under Different Phases of Clinical Development Like -
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
The Ovarian Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Oral
Parenteral
Intravitreal
Subretinal
Topical.
Molecule Type
Products have been categorized under various Molecule types, such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Request for Sample PDF to Understand More About the Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/sample-request/ovarian-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Ovarian Cancer Therapeutics Analysis
There are approx. 100+ key companies developing therapies for Ovarian Cancer. Currently, Genentech is leading the therapeutics market with its Ovarian Cancer drug candidates in the most advanced stage of clinical development.
The Leading Players in the Ovarian Cancer Therapeutics Market Include:
AB Science, Acerta Pharma, AIM ImmunoTech Inc., Allarity Therapeutics, Apexigen, Aprea Therapeutics, Aravive, Inc., Arcus Biosciences, AstraZeneca, Bayer, BeiGene, BioNumerik, Celsion, Chipscreen Biosciences, Clovis Oncology, Cristal Therapeutics, CSPC ZhongQi Pharmaceutical, DCPrime BV, Eli Lilly and Company, Ellipses Pharma, Genentech, Genmab, Gilead Sciences, GlaxoSmithKline, Hoffmann-La Roche, Hrain Biotechnology Co., Ltd., Immunitor LLC, Impact Therapeutics, Inc., Jiangxi Qingfeng Pharmaceutical Co. Ltd., Laekna Limited, MedImmune, Merck KGaA, Novartis Oncology, On Target Laboratories, Pfizer, PharmaMar, Pharmicell Co., Ltd., Plexxikon, PTC Therapeutics, Regeneron Pharmaceuticals, Shattuck Labs, Inc., Syndax Pharmaceuticals, Tesaro, Inc., VBL Therapeutics, Verastem, Inc., and others.
Ovarian Cancer Emerging and Marketed Drugs Covered in the Report Include:
Atezolizumab: Genentech
Tisotumab Vedotin: Genmab
Pembrolizumab: Merck
IMGN151: ImmunoGen
AVB-500: Aravive
SL-172154: Shattuck Labs, Inc
DS-6000: Daiichi Sankyo
2X-121: Allarity Therapeutics
And Many More
Get an in-depth Assessment of the Emerging Therapies and Key Companies:
https://www.delveinsight.com/sample-request/ovarian-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Ovarian Cancer Current Treatment Patterns
4. Ovarian Cancer - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Ovarian Cancer Late-Stage Products (Phase-III)
7. Ovarian Cancer Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Ovarian Cancer Discontinued Products
13. Ovarian Cancer Product Profiles
14. Ovarian Cancer Key Companies
15. Ovarian Cancer Key Products
16. Dormant and Discontinued Products
17. Ovarian Cancer Unmet Needs
18. Ovarian Cancer Future Perspectives
19. Ovarian Cancer Analyst Review
20. Appendix
21. Report Methodology
Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/ovarian-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Other Trending Reports by DelveInsight-)
- Indolent Lymphoma Market
https://www.delveinsight.com/report-store/indolent-lymphoma-market
- Liver Angiosarcoma Market
https://www.delveinsight.com/report-store/liver-angiosarcoma-market
- Osteochondrodysplasia Market
https://www.delveinsight.com/report-store/osteochondrodysplasia-market
- Metastatic Cutaneous Squamous Cell Carcinoma Market
https://www.delveinsight.com/report-store/metastatic-cutaneous-squamous-cell-carcinoma-market
- Nocturnal Enuresis Market
https://www.delveinsight.com/report-store/nocturnal-enuresis-market
- Undifferentiated Pleomorphic Sarcoma Market
https://www.delveinsight.com/report-store/undifferentiated-pleomorphic-sarcoma-market
- Mucinous cystic neoplasms (MCNs) Market
https://www.delveinsight.com/report-store/mucinous-cystic-neoplasms-mcns-market
- Tuberous Sclerosis Complex Market
https://www.delveinsight.com/report-store/tuberous-sclerosis-complex-market
- Hypersomnia Market
https://www.delveinsight.com/report-store/hypersomnia-market
- Ocular Melanoma Market
https://www.delveinsight.com/report-store/ocular-melanoma-market
- Mucopolysaccharidosis I Market
https://www.delveinsight.com/report-store/mucopolysaccharidosis-i-market
- Bone Resorption Market
https://www.delveinsight.com/report-store/bone-resorption-market
- Chronic Refractory Gout Market
https://www.delveinsight.com/report-store/chronic-refractory-gout-market
- Complicated Intra-Abdominal Infections Market
https://www.delveinsight.com/report-store/complicated-intra-abdominal-infections-market
- Duchenne Muscular Dystrophy Market
https://www.delveinsight.com/report-store/duchenne-muscular-dystrophy-market
- Gonorrhea Market
https://www.delveinsight.com/report-store/gonorrhea-market
- Hypercalcemia Market
https://www.delveinsight.com/report-store/hypercalcemia-market
- Lenegre's disease Market
https://www.delveinsight.com/report-store/lenegres-disease-market
- Mitochondrial Myopathies Market
https://www.delveinsight.com/report-store/mitochondrial-myopathies-market
- Mucinous cystic neoplasms (MCNs) Market
https://www.delveinsight.com/report-store/mucinous-cystic-neoplasms-mcns-market
- Obsessive-Compulsive Disorder Market
https://www.delveinsight.com/report-store/obsessive-compulsive-disorder-market
- Osteochondromas Market
https://www.delveinsight.com/report-store/osteochondromas-market
- Preeclampsia Market
https://www.delveinsight.com/report-store/preeclampsia-market
- Uterine Serous Carcinoma Market
https://www.delveinsight.com/report-store/uterine-serous-carcinoma-market
- Vasomotor symptoms (Hot flashes/Night sweats) Market
https://www.delveinsight.com/report-store/vasomotor-symptoms-market
- Venous Leg Ulcer Market
https://www.delveinsight.com/report-store/venous-leg-ulcer-market
Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Ovarian Cancer Pipeline Analysis (2023 Updates) | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, Treatment Outlook, and Key Companies | Genentech, Genmab, Merck, ImmunoGen, Aravive, here
News-ID: 3033652 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Ovarian
Ovarian Cancer Market Size, Future Trends
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- The global Ovarian Cancer Market is expected to record a CAGR of XX.X% from 2024 to 2031 In 2024, the market size is projected to reach a valuation of USD XX.X Billion. By 2031 the valuation is anticipated to reach USD XX.X Billion.
The impact of manufacturers on the market is significant across various industries, influencing supply chains, consumer choices, and economic growth. Manufacturers are key players in…
Polycystic Ovarian Syndrome Treatment Market Report
The findings reviewed by GME stated that the Global Polycystic Ovarian Syndrome Treatment Market will expand with a CAGR value of 5.2 percent from 2021 to 2026. The rising incidence of PCOS increased understanding among a group of patients, and the growing acceptance of standard treatment boosts the PCOS treatment industry growth over the projected timeframe. Furthermore, the research and development of PCOS are predicted to aid in market growth.
Browse…
Ovarian Cancer Drugs Market Report 2020-2030
Forecasts by Therapeutic Class (PARP, PD-L1, Angiogenesis Inhibitors) Plus Analysis of Leading Companies
Download free sample pages: https://www.visiongain.com/report/ovarian-cancer-drugs-market-report-2020-2030/
Ovarian Cancer Drugs Market- our new study reveals trends, R&D progress, and predicted revenues
Where the Ovarian Cancer Drugs is market heading? If you are involved in this industry you must read this newly updated report. Visiongain's report shows you the potential revenues streams to 2030, assessing data, trends, opportunities and business prospects there.
Discover…
How deadly is Ovarian Cancer?
Ovarian Drugs and Treatment Market describes its growth, size, share, Forecast and trends to 2025
Ovarian cancer is a cancer that forms in or on an ovary. It results in abnormal cells that have the ability to invade or spread to other parts of the body.
The global Ovarian Cancer Treatment Drugs market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025,…
Polycystic Ovarian Syndrome Treatment Market - Regional Analysis
The organic and inorganic strategies by the market players will boost the polycystic ovarian syndrome treatment market. For instance, in 2016, Millendo Therapeutics, Inc., a biopharmaceutical company, entered into an exclusive license agreement with AstraZeneca for the development and commercialization of phase II entered AZD4901, a candidate product for the treatment of polycystic ovarian syndrome. Moreover, in 2017, Astellas Pharma Inc. completed its acquisition of Ogeda SA (formerly Euroscreen S.A.).…
Ovarian Cancer - Heat Map and Analysis
ReportsWorldwide has announced the addition of a new report title Ovarian Cancer - Heat Map and Analysis to its growing collection of premium market research reports.
Ovarian Cancer (OC) is the fifth most common malignancy diagnosed in women, and the most common gynecological cancer, with an estimated 225,000 new cases diagnosed globally in 2008. Rates are particularly high in developed countries, and especially in Northern Europe. However, substantial improvements in…
